Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) - Total Assets
Based on the latest financial reports, Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) holds total assets worth CN¥2.89 Billion CNY (≈ $423.37 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore 300357 operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd - Total Assets Trend (2009–2024)
This chart illustrates how Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. See what is Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's book value for net asset value and shareholders' equity analysis.
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's total assets of CN¥2.89 Billion consist of 61.0% current assets and 39.0% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 41.3% |
| Accounts Receivable | CN¥257.87 Million | 9.5% |
| Inventory | CN¥57.73 Million | 2.1% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥181.53 Million | 6.7% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2009–2024)
This chart illustrates how Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's current assets represent 61.0% of total assets in 2024, a decrease from 62.2% in 2009.
- Cash Position: Cash and equivalents constituted 41.3% of total assets in 2024, up from 35.8% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, a decrease from 10.0% in 2009.
- Asset Diversification: The largest asset category is accounts receivable at 9.5% of total assets.
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Zhejiang Wolwo Bio-Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biogen Inc
NASDAQ:BIIB
|
USA | $29.44 Billion |
|
Pfizer Inc
SA:PFIZ34
|
Brazil | R$207.62 Billion |
|
AstraZeneca PLC
NYSE:AZN
|
USA | $114.02 Billion |
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SHG:600436
|
China | CN¥18.38 Billion |
|
Aurora Optoelectronics Co Ltd
SHG:600666
|
China | CN¥2.22 Billion |
|
NanJing Pharmaceutical Co Ltd
SHG:600713
|
China | CN¥34.05 Billion |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3
|
Brazil | R$3.66 Billion |
|
Firebrick Pharma Ltd
AU:FRE
|
Australia | AU$2.28 Million |
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 14.78 | 10.09 | 21.13 |
| Quick Ratio | 14.33 | 9.77 | 20.26 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.65 Billion | CN¥1.49 Billion | CN¥1.12 Billion |
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.43 |
| Latest Market Cap to Assets Ratio | 0.66 |
| Asset Growth Rate (YoY) | 5.7% |
| Total Assets | CN¥2.71 Billion |
| Market Capitalization | $1.80 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's assets below their book value (0.66x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's assets grew by 5.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (2009–2024)
The table below shows the annual total assets of Zhejiang Wolwo Bio-Pharmaceutical Co Ltd from 2009 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.71 Billion ≈ $396.43 Million |
+5.74% |
| 2023-12-31 | CN¥2.56 Billion ≈ $374.93 Million |
+16.57% |
| 2022-12-31 | CN¥2.20 Billion ≈ $321.62 Million |
+13.76% |
| 2021-12-31 | CN¥1.93 Billion ≈ $282.71 Million |
+20.39% |
| 2020-12-31 | CN¥1.60 Billion ≈ $234.83 Million |
+12.36% |
| 2019-12-31 | CN¥1.43 Billion ≈ $208.99 Million |
+35.01% |
| 2018-12-31 | CN¥1.06 Billion ≈ $154.80 Million |
+24.71% |
| 2017-12-31 | CN¥848.31 Million ≈ $124.13 Million |
+21.73% |
| 2016-12-31 | CN¥696.89 Million ≈ $101.98 Million |
+13.97% |
| 2015-12-31 | CN¥611.49 Million ≈ $89.48 Million |
+15.09% |
| 2014-12-31 | CN¥531.31 Million ≈ $77.75 Million |
+101.29% |
| 2013-12-31 | CN¥263.95 Million ≈ $38.62 Million |
+38.11% |
| 2012-12-31 | CN¥191.11 Million ≈ $27.97 Million |
+29.84% |
| 2011-12-31 | CN¥147.19 Million ≈ $21.54 Million |
+33.17% |
| 2010-12-31 | CN¥110.52 Million ≈ $16.17 Million |
-8.95% |
| 2009-12-31 | CN¥121.38 Million ≈ $17.76 Million |
-- |
About Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceutical products for the diagnosis and treatment of allergic diseases in China and internationally. The company offers Changdi, a dust mine drops; Changhao, an artemisia annua pollen allergen sublingual drops; and Changdian, a dust mite skin prick diagnost… Read more